IL33 and breast cancer: The potential of inducing the expression of the tumor‐derived alarmin IL‐33 and consequently eosinophil accumulation has also been previously described, using the dipeptidyl peptidase DPP4 (CD26) inhibitor sitagliptin in multiple solid tumors in vivo, including breast cancer models [15].